Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

• Elisa Agostinetto,
• Evandro de Azambuja,
• Matteo Lambertini

Affiliations

Elisa Agostinetto

Institut Jules Bordet and l’Université Libre de Bruxelles

Evandro de Azambuja

Institut Jules Bordet and l’Université Libre de Bruxelles

Matteo Lambertini

Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova